PHAT

Phathom Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website athompharma.com
Employees(FY) 112
ISIN US71722W1071

Performance

-8.3%

-45.71%

-32.27%

-17.17%

-4.38%

YTD

+17.81%

Profile

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Advanced Technical Analysis

Technical Analysis of PHAT 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors, as the prevailing trend appea...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PHAT

Stock Rank

Recent News & Updates

2024-11-19 12:00
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know(Zacks)
2024-11-08 06:02
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...(GuruFocus.com)
2024-11-07 10:34
Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens(MT Newswires)
2024-11-07 09:20
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates(Zacks)
2024-11-07 08:00
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates(GlobeNewswire)
2024-11-06 19:00
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates(Globenewswire)
2024-11-06 07:21
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For(GuruFocus.com)
2024-11-04 08:00
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-11-03 19:00
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-01 09:36
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%(Simply Wall St.)
2024-10-28 08:00
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024(GlobeNewswire)
2024-10-27 20:00
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024(Globenewswire)
2024-10-27 12:00
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting(GlobeNewswire)
2024-10-27 00:00
Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting(Globenewswire)
2024-08-29 08:00
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-08-28 20:00
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-19 09:14
Phathom Pharmaceuticals Prices Underwritten Offering of Shares and Warrants(MT Newswires)
2024-08-19 08:00
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants(GlobeNewswire)
2024-08-18 20:00
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants(Globenewswire)
2024-08-08 09:20
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates(Zacks)
2024-08-08 08:00
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update(GlobeNewswire)
2024-08-07 20:00
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-07-30 08:00
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients(GlobeNewswire)
2024-07-29 20:00
Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients(Globenewswire)
2024-07-29 07:59
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024(GlobeNewswire)
2024-07-28 19:59
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024(Globenewswire)
2024-07-18 10:24
Phathom Pharmaceuticals Gets New FDA Approval for Voquezna Tablets(MT Newswires)
2024-07-18 08:38
Daily – Vickers Top Buyers & Sellers for 07/18/2024(Argus Research)
2024-07-18 08:00
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults(GlobeNewswire)
2024-07-17 20:00
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults(Globenewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.